Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience

The aim of our study was to characterize the repolarization disorders propensity induced by drug-drug interaction. In this observational retrospective study, we report experience on all elderly patients with ascertained diagnosis coronavirus disease 2019 through nasopharyngeal swab real time-polymerase chain reaction at Pugliese-Ciaccio hospital in Catanzaro, who received hydroxychloroquine (HCQ), or without azithromycin (AZY). 33 hospitalized were examined. We calculated QT value, cQT, dispersion, and cQT dispersion examined possible progression basal electrocardiogram (T0) after insertion drug (T1). value is increased T0 vs T1 (370±40.74 420±36.91 ms; P=0.000), as well (408±25.40 451.54±58.81; P=0.003), (QTd: 36.36±14.53 50.90±13.12 P=0.000); cQTc (cQTd 46.27±18.72 63.18±21.93 P=0.001). ΔQT 37.44±44.09 while ΔcQT 32.01±56.47). main determinant QTc prolongation number risk that could influence ventricular phase. use HCQ combination AZY, suffering from severe acute respiratory syndrome-related coronavirus-2, can favor onset serious side effects, even potentially fatal. Finally, measures QTd cQTd confirmed additional electrocardiographic parameters useful identifying being treated drugs potential adverse arrhythmic events following